Drug Trial Radar · NCT06791772
Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)
Last checked: Nov 19, 2026Latest source record: Jan 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Feb 2025
Primary completion
Oct 2026
Study completion Feb 2027
Sponsor
- Lead sponsor
- Keymed Biosciences Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of CM313(SC) injection in systemic lupus erythematosus(SLE)
Conditions
- Systemic Lupus Erythematosus
Interventions
CM313 injectionBiological
CM313 600mg(4ml)/vial. Subcutaneous injection 600mg. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.
CM313 injectionBiological
CM313 600mg(4ml)/vial. Subcutaneous injection 1200mg. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.
PlaceboDrug
Placebo 4 mL/vial. Subcutaneous injection 4 or 8 mL. The first 5 doses were administered weekly, followed by every two weeks, a total of 14 doses.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects achieving Systemic Lupus Erythematosus Responder Index -4 (SRI-4)Time frame: Up to week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.